Human Menstrual Blood-Derived Mesenchymal Stem Cells as Potential Cell Carriers for Oncolytic Adenovirus

Figure 3

Tumor tropism of MenSCs. (a) A549 tumor-bearing immunodeficient mice () were administered with 1 × 10⁶ DiR-labeled MenSCs intratumorally (IT) or intraperitoneally (IP), and fluorescence signal was detected using an in vivo imaging system (IVIS) at the indicated time points after cell administration. At the end of the experiment (5d), tumors were harvested and exposed to fluorescence analysis. (b) Intensity of fluorescence in tumors was quantified with the IVIS living image software. Mean values () ± SD are represented. (c) To evaluate the impact of OAdv infection on tumor-homing capacity of MenSCs and BM-MSCs, A549 tumor-bearing immunodeficient mice () were injected intraperitoneally with 1 × 10⁶ of BM-MSCs (previously labeled with DiR), MenSCs (previously labeled with DiR), BM-MSCs-OAdv (BM-MSCs previously infected with ICOVIR15 at MOI 50 for 2 h and labeled with DiR), and MenSCs-OAdv (MenSCs previously infected with ICOVIR15 at MOI 50 for 2 h and labeled with DiR). Fluorescence signal was detected using IVIS at the indicated time points after cell administration. (d) Intensity of tumor fluorescence was quantified with IVIS software. Mean values () ± SD are plotted. No statistical differences in tumor fluorescence values were observed between mesenchymal from different origins (bone marrow versus menstrual blood) and between infected and noninfected cells for each cell type (BM-MSC versus BM-MSC + OAdv and MenSC versus MenSC + OAdv) at any time points analyzed (Mann–Whitney U test).

(a)

(b)

(c)

(d)